Navigation Links
Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
Date:11/19/2009

RYE, N.Y., Nov. 19 /PRNewswire/ -- Curemark LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company has begun enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at three additional clinical trial sites. The sites are the Southwest Autism and Resource Center in Phoenix, Arizona (SARRC); Pennsylvania State University's Pediatric Clinical Research Office at Hershey Medical Center in Hershey Pennsylvania; and the University of North Carolina at Chapel Hill.

Curemark is conducting Phase III clinical trials for CM-AT at 12 sites with a total 170 children across the country. The company previously announced that the first clinical trial patients were enrolled at Lake Mary Pediatrics in Orange City, Florida.

"We are extremely pleased with the progress of the Phase III trial enrollment for CM-AT and are continuing to move forward with the other sites in the study across the country," said Dr. Joan Fallon, Curemark founder and CEO. "Especially given the new data on the increased incidence of autism, we're excited to be this far along in our clinical program."

CM-AT is based on Fallon's breakthrough research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. CM-AT will be one of the first therapies to address the underlying physiology of autism, rather than just treat its symptoms.

A new study released in early October by the U.S. Centers for Disease Control (CDC) showed that the number of children affected by autism is much higher than originally thought. According to the CDC, autism affects 1 in 91 children and about 1 in 58 boys, totaling an estimated 673,000 or approximately 1% of all children in the U.S.

For information on participating in the CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark LLC


'/>"/>
SOURCE Curemark LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
2. Curemark Announces Senior Executive Promotions
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Closes Series A Financing
5. Curemark Appoints Preeminent Pediatrics Gastroenterologist
6. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
7. Eli Lilly and Company Opens Eco-Friendly Biotechnology Center on the West Coast Designed to Speed and Enhance Innovation
8. Center for Community Health Opens in Skid Row to Provide Healthcare Services to Nearly 9,000 Patients Annually
9. Whistleblowers Attorney Says Pfizers Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies
10. TCP Innovations Opens First US Office
11. New Places and People - Truphatek opens USA subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):